48Weeks Follow-up Of Patients With E Antigen Positive Chronic Hepatitis B Treated By Peginterferon Alfa-2a

Objective：Follow-up48weeks clinical outcome of patients with eantigen positive chronic hepatitis B after treated by pegylated interferonalpha-2a.Methods: A total of162patients were included in the study. Allpatients with e antigen positive chronic hepatitis B receiving180gpeginterferon alfa-2a once-weekly for48weeks. During the48weekstreatment，the analine aminotransferase(ALT), white blood cell (WBC),platelet (PLT) were examined once every4weeks, and responses includingHBsAg, HBeAg seroconversion and HBV DNA suppression were measuredonce every12weeks，and abdominal ultrasound、AFP were examined everysix months. After the end of the48weeks of treatment, we followed up for48weeks again. During the period of48weeks follow-up, HBsAg, HBeAgseroconversion and HBV DNA suppression were measured once every12weeks，and abdominal ultrasound、AFP were examined every six months.Results: Mean HBV DNA level at baseline was （6.58±0.90） log10copies/mL. At the end of the48weeks post-treatment sustained HBeAgseroconversion was achieved by40.12%(65/162)，41.98%(68/162) patients developed virological response HBV-DNA.1patients sustaintedHBsAg seroconversion. During the follow-up of48weeks，seventy patients（70/162，43.21%）had hepatitis B surface antigen(HBsAg) seroconversionand fifty-nine（59/162，36.42%）patients developed virological responseHBV-DNA. But there are ten patients（10/162，6.17%） experiencedvirological rebound. No unexpected adverse events were reported.Conclusions: Pegylated interferon alpha-2a can sustain the serologicalHBeAg stable conversion at the end of treatment，and suppression ofHBV-DNA replication.But there are a few patient with virological reboundafter the end of treatment. The baseline ALT level, age, virological responsetime, baseline quantitative level of HBV-DNA had no significantrelationship between the virological rebound.